A pharmaceutical giant in Japan, Takeda, recently came up with a vaccine against dengue fever, TAK-003, which they claim can provide protection for 4.5 years, according to CNA.
Advertisements
Takeda said that their vaccine has shown an 84% efficacy rate at preventing hospitalisations and 61% at stopping symptomatic hospitalisations.
They also claim that no important safety risks have emerged.
At the moment, only Dengvaxia has been approved to be used as a vaccine across the world, but only those who have recovered from dengue can take it; while TAK-003 is meant for both the infected and uninfected.
The vaccine was recently submitted for approval in Europe and other countries that are “dengue-endemic” like Singapore.
Advertisements